An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women

PHASE3CompletedINTERVENTIONAL
Enrollment

436

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

May 14, 2015

Study Completion Date

May 14, 2015

Conditions
Postmenopausal Osteoporosis
Interventions
DRUG

Romozosumab

Administered by subcutaneous injection once a month.

DRUG

Teriparatide

Administered by subcutaneous injection once a day.

Trial Locations (50)

1036

Research Site, Budapest

1083

Research Site, Budapest

1123

Research Site, Budapest

2650

Research Site, Hvidovre

2750

Research Site, Ballerup Municipality

3000

Research Site, Leuven

3400

Research Site, Hillerød

3600

Research Site, Genk

4000

Research Site, Liège

5000

Research Site, Odense

6700

Research Site, Esbjerg

8000

Research Site, Aarhus C

9000

Research Site, Ghent

Research Site, Aalborg

18012

Research Site, Granada

20817

Research Site, Bethesda

28041

Research Site, Madrid

28046

Research Site, Madrid

28223

Research Site, Pozuelo de Alarcón

30501

Research Site, Gainesville

48236

Research Site, Detroit

02114

Research Site, Boston

02131

Research Site, Boston

C1012AAR

Research Site, Ciudad Autonoma de Buenos Aires

C1128AAF

Research Site, Ciudad Autonoma de Buenos Aires

X5000BNB

Research Site, Córdoba

T2N 4Z6

Research Site, Calgary

V6H 3X8

Research Site, Vancouver

M5C 2T2

Research Site, Toronto

M5G 2C4

Research Site, Toronto

G1V 3M7

Research Site, Québec

Unknown

Research Site, Medellín

08001000

Research Site, Barranquilla

602 00

Research Site, Brno

702 00

Research Site, Ostrava

305 99

Research Site, Pilsen

148 00

Research Site, Praha 11 - Chodov

686 01

Research Site, Uherské Hradiště

81-384

Research Site, Gdynia

40-040

Research Site, Katowice

01-192

Research Site, Warsaw

50-088

Research Site, Wroclaw

08041

Research Site, Barcelona

08907

Research Site, LHospitalet de Llobregat

CF14 5GJ

Research Site, Cardiff

PR7 7NA

Research Site, Chorley

L22 0LG

Research Site, Liverpool

HA6 2RN

Research Site, Northwood

RG2 0TG

Research Site, Reading

DA14 6LT

Research Site, Sidcup

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT01796301 - An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women | Biotech Hunter | Biotech Hunter